- The family of Huw Jones, who died from bile duct cancer, is campaigning for the NHS to approve a new treatment called zanidatamab, which significantly improved his quality of life.
- Jones, from north Wales, was diagnosed with stage 4 cholangiocarcinoma and started taking zanidatamab in a clinical trial, allowing him to spend a year with his family after his son's birth.
- NICE, the NHS's spending watchdog, initially rejected the targeted treatment for widespread use but is scheduled to reassess further evidence in March.
- Another patient, NHS surgeon Gareth Honeybone, also experienced significant benefits from zanidatamab in a clinical trial, with scans showing his tumour is no longer visible.
- Charities and patients emphasise that zanidatamab offers longer life and improved quality of life for those with HER2-positive bile duct cancer, a condition with very poor survival rates.
IN FULL
NHS urged to approve new treatment for aggressive cancer after tumours shrink in size
